Investor's Business Daily on MSN14h
IBD Composite Rating For Carpenter Technology Stock Rises To 96
The IBD SmartSelect Composite Rating for Carpenter Technology rose from 93 to 96 Wednesday. The specialty steel stock sports ...
Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds
Takeda Pharmaceutical has a robust drug discovery pipeline to meet future clinical demand. Check out the upside and downside ...
Medscape21h
Difficult-to-Treat IBD Patients Prefer Dual Biologic Therapy
Dual biologic therapy may serve as a suitable treatment choice for patients with IBD who have not responded to current therapies.
Investor's Business Daily on MSN11h
Ryan Specialty, IBD Stock Of The Day, Eyes Buy Point After Finding Key Support
Ryan Specialty boasts accelerating growth and rising relative strength. Ryan Specialty stock is nearing a buy point.
The American Journal of Managed Care13h
Clarifying the Role of EEN Diet as Ulcerative Colitis Therapy
There is insufficient evidence to support exclusive enteral nutrition as an adjunctive therapy for active ulcerative colitis, ...
Halma Good Progress in 2H
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
Gastroenterology Advisor20h
Severe Obesity and Bariatric Surgery Independently Increase Risk for IBD
A retrospective population-based study showed that severe obesity and bariatric surgery independently increased the risk of inflammatory bowel disease.